- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Swedish Firm Honored for Rare Disease Treatments
Swedish Orphan Biovitrum AB (Sobi) was last night presented with a EURORDIS Award for its commercial and development portfolio in the field of rare diseases.
Swedish Orphan Biovitrum AB (Sobi) was last night presented with a EURORDIS Award for its commercial and development portfolio in the field of rare diseases. The award also recognized the company’s track record on access to drugs and its collaboration with patient organizations.
EURORDIS is Europe’s largest patient organization in rare diseases. Its CEO, Yann Le Camm, commented: “We are honored to acknowledge the commitment and achievements of the recipients of the EURORDIS Awards on the occasion of Rare Disease Day 2014.” This year, he added, Rare Disease Day puts the spotlight on care.
Sobi’s CEO, Geoffrey McDonough, said: “We are inspired to pioneer a world in which rare disease patients are diagnosed at birth,receive effective and sustainable therapy, and go on to live full and healthy lives.”
Other winners at the EURORDIS AWards included Orphan Europe, part of the Recordati group, which has nearly 25 years’ experience in bringing orphan drugs to market for rare diseases with seven products to date.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
